MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

MSD has opened the doors of a $1 billion manufacturing facility at its site in Durham, North Carolina, that will be used to ...

In a decision signed Monday, North Carolina federal judge Kenneth Bell granted Merck’s motion to dismiss the claims of ...

Merck opens new, $1 billion, 225,000-sq ft facility dedicated to vaccine manufacturing at its Durham, North Carolina, site: Durham, North Carolina Wednesday, March 12, 2025, 09:00 ...

Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

Merck & Co. (MSD outside the U.S. and Canada) has just unveiled a brand-new, cutting-edge vaccine manufacturing facility at ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Their CryptoMap platform leverages immunopeptidomics, genomics, and a bioinformatics pipeline, allowing the identification of ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

This expansion of our Durham plant is a crucial component of the more than $12 billion Merck has invested toward U.S. capital ...